A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

Study Purpose

The aim of the trial is to study the long-term safety of macitentan and to provide continued treatment with macitentan to patients with pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH) who were previously treated with macitentan in clinical studies.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages N/A and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Signed informed consent to take part in the study before any study mandated procedure. 2. Participants from one of the parent studies and: a) the sponsor has decided to terminate the parent study in that country and b) the participant has completed the end of treatment (EOT) Visit of the parent study 3. Women of childbearing potential are able to take part in the study if the following applies: a) Urine pregnancy test is negative at Enrollment; b) Agreement to perform monthly urine or serum pregnancy tests during the study and up to at least 30 days after the study treatment discontinuation; and c) Agreement to adhere to the planned contraception scheme from Enrollment up to at least 30 days after study treatment discontinuation

Exclusion Criteria:

1. Hemoglobin less than 80 gram per liter (g/L) 2. Serum Aspartate aminotransferase (AST) and/or alanine aminotransferases (ALT) more than three times the upper limit of normal range 3. Known and documented history of severe hepatic impairment that is Child-Pugh Class C. 4. Pregnant, planning to become pregnant, or breastfeeding 5. Known hypersensitivity to macitentan, its excipients, or drugs of the same class 6. Planned or current treatment with another investigational treatment up to 3 months prior to Enrollment 7. Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results, such as drug or alcohol dependence or psychiatric disease 8. Treatment with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Thomas Pfister, PhD
Principal Investigator Affiliation Actelion
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Enrolling by invitation
Countries Belarus, France, Ukraine

The disease, disorder, syndrome, illness, or injury that is being studied.

Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Additional Details

The purpose of this study is to provide continued treatment with macitentan to subjects with PAH or CTEPH who participated in "parent studies" and to continue to accrue long-term safety data. The design of this study is widely used in clinical programs to give participants in a clinical study access to an effective study treatment beyond completion of the parent study. This is considered the best option to collect long-term safety and tolerability information of macitentan 10 mg and survival status of participants with PAH and CTEPH. "Parent study/studies" refer to a number of clinical studies with macitentan that are conducted in different clinical classification of PAH and CTEPH (NCT00667823, NCT02112487, NCT02310672, NCT02968901, NCT02558231, NCT02382016, NCT02060721) and may be completed before the participants have access to commercial macitentan in their country of residence. The "parent studies" are fully or partially running in countries where no access to commercial macitentan is expected in the near future.

Arms & Interventions


Experimental: Open-label macitentan 10 mg

10 mg macitentan film coated tablet, administered orally once daily


Drug: - macitentan

macitentan 10 mg, film-coated tablet, oral use

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Minsk, Belarus



The Republican Scientific-Practical Center "Cardiology"

Minsk, , 220036

CHRU de Besançon, Hôpital Jean Minjoz, Besançon, France



CHRU de Besançon, Hôpital Jean Minjoz

Besançon, , 25030

CHU de Bordeaux, Hôpital de Haut Levêque, Bordeaux, France



CHU de Bordeaux, Hôpital de Haut Levêque

Bordeaux, , 33604

CHU de la Cavale Blanche, Brest, France



CHU de la Cavale Blanche

Brest, , 29609

CHU de la Côte de Nacre, Caen, France



CHU de la Côte de Nacre

Caen, , 14033

CHU de Dijon, Dijon, France



CHU de Dijon

Dijon, , 21079

Grenoble, France



CHU de Grenoble, Clinique Univ Pneumo Pôle Thorax et Vaisseaux

Grenoble, , 38700

Le Kremlin-Bicêtre, France



Service de pneumologie et Réanimation Respiratoire, CHU de Bicêtre

Le Kremlin-Bicêtre, , 94275

CHRU de Lille, Hôpital cardiologique, Lille, France



CHRU de Lille, Hôpital cardiologique

Lille, , 59037

CHU de Limoges - Hôpital Dupuytren 2, Limoges, France



CHU de Limoges - Hôpital Dupuytren 2

Limoges, , 87042

HCL, Hôpital Louis Pradel, Lyon, France



HCL, Hôpital Louis Pradel

Lyon, , 69667

CHU de la Timone, Marseille, France



CHU de la Timone

Marseille, , 13385

Montpellier, France



CHU de Montpellier, Hôpital Arnaud de Villeneuve

Montpellier, , 34295

CHU de Nantes, Hôpital Nord Laennec, Nantes, France



CHU de Nantes, Hôpital Nord Laennec

Nantes, , 44093

CHU de Nice, Hôpital Pasteur, Nice, France



CHU de Nice, Hôpital Pasteur

Nice, , 06001

CHU de Reims, Reims, France



CHU de Reims

Reims, , 51100

CHU de Rennes, Hôpital Pontchaillou, Rennes, France



CHU de Rennes, Hôpital Pontchaillou

Rennes, , 35033

Rouen, France



CHU de Rouen Normandie, Hôpital Charles Nicolle

Rouen, , 76031

CHU de Saint-Etienne, Hôpital Nord, Saint-Etienne, France



CHU de Saint-Etienne, Hôpital Nord

Saint-Etienne, , 42000

CHRU de Strasbourg, Hôpital Civil, Strasbourg, France



CHRU de Strasbourg, Hôpital Civil

Strasbourg, , 67091

CHU de Toulouse, Hôpital Larrey, Toulouse, France



CHU de Toulouse, Hôpital Larrey

Toulouse, , 31059

CHU de Nancy, Hôpitaux de Brabois, Vandoeuvre Les Nancy, France



CHU de Nancy, Hôpitaux de Brabois

Vandoeuvre Les Nancy, , 54511





Dnipro, , 49070

Lviv, Ukraine




Lviv, , 79010

For more information, please contact PHA at Research@PHAssociation.org and refer to the terms of service below.

Submit Feedback

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation in a clinical trial or study.